Close
Help





JOURNAL

Clinical Medicine Reviews in Therapeutics

Almotriptan Malate: Early Treatment in Acute Migraine

Submit a Paper


Clinical Medicine Reviews in Therapeutics 2012:4 41-50

Review

Published on 12 Jan 2012

DOI: 10.4137/CMRT.S1568


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract

Abstract: Almotriptan is a selective serotonin agonist used for the relief of moderate to severe migraine headaches. Clinical trials have begun to evaluate its use in the ‘early’ treatment of migraines, described as when a triptan is administered within 1 hour of the onset of headache for mild pain. These trials have demonstrated higher pain-free rates, decreased recurrence of migraines, and a reduction in the need for rescue medication compared to when the treatment is delayed until the pain is moderate to severe in intensity or beyond 1 hour of headache onset. Tolerability and safety of almotriptan for 'early' use is similar to standard administration of the medication.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services